View in EDS

2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome.

Saved in:
Bibliographic Details
Title: 2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome.
Authors: Subramani R; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.; Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States., Chatterjee A; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States., Pedroza DA; Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States., Poudel S; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States., Rajkumar P; College of Osteopathic Medicine, Rocky Vista University, Ivins, UT, United States., Annabi J; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States., Penner E; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States., Lakshmanaswamy R; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.; Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States.
Source: Frontiers in oncology [Front Oncol] 2024 Sep 12; Vol. 14, pp. 1371792. Date of Electronic Publication: 2024 Sep 12 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39328201
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Subramani+R%22">Subramani R</searchLink>; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.; Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States.<br /><searchLink fieldCode="AU" term="%22Chatterjee+A%22">Chatterjee A</searchLink>; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.<br /><searchLink fieldCode="AU" term="%22Pedroza+DA%22">Pedroza DA</searchLink>; Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States.<br /><searchLink fieldCode="AU" term="%22Poudel+S%22">Poudel S</searchLink>; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.<br /><searchLink fieldCode="AU" term="%22Rajkumar+P%22">Rajkumar P</searchLink>; College of Osteopathic Medicine, Rocky Vista University, Ivins, UT, United States.<br /><searchLink fieldCode="AU" term="%22Annabi+J%22">Annabi J</searchLink>; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.<br /><searchLink fieldCode="AU" term="%22Penner+E%22">Penner E</searchLink>; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.<br /><searchLink fieldCode="AU" term="%22Lakshmanaswamy+R%22">Lakshmanaswamy R</searchLink>; Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, United States.; Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2024 Sep 12; Vol. 14, pp. 1371792. <i>Date of Electronic Publication: </i>2024 Sep 12 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39328201
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2024.1371792
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1371792
    Titles:
      – TitleFull: 2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Subramani R
      – PersonEntity:
          Name:
            NameFull: Chatterjee A
      – PersonEntity:
          Name:
            NameFull: Pedroza DA
      – PersonEntity:
          Name:
            NameFull: Poudel S
      – PersonEntity:
          Name:
            NameFull: Rajkumar P
      – PersonEntity:
          Name:
            NameFull: Annabi J
      – PersonEntity:
          Name:
            NameFull: Penner E
      – PersonEntity:
          Name:
            NameFull: Lakshmanaswamy R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 09
              Text: 2024 Sep 12
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1